2nd Tumour Models Summit Malmo

Selecting and Optimising Predictive and Cost-Effective Models to Enhance Target Selection, Facilitate Biomarker Discovery and Achieve Clinical Translatability
2026 is set to reshape the future of preclinical oncology.

As we close out 2025 with the UK accelerating its roadmap to phase out animal testing and SillaJen securing a landmark FDA approval using only organoid efficacy data, the momentum has never been stronger. With immunomodulating therapies surging and preclinical development costs continuing to climb, the pressure is on for biopharma to cut attrition and de-risk every preclinical decision.

The message is clear: investing in more trustworthy, physiologically relevant, and cost-effective models is now mission-critical for successfully advancing assets worldwide.

Join your peers at the Tumour Models Summit Malmo as the industry's leading minds unite to navigate this paradigm shift and define the future of preclinical oncology.


URLs:
Website: https://go.evvnt.com/3467771-0?pid=2874
Brochure: https://go.evvnt.com/3467771-3?pid=2874

Category: Conferences | Science, Health and Medicine

Prices:
Conference Only - Drug Developer Pricing: SEK 0.00,
Conference Only - Service Provider Pricing: SEK 3499.00

Speakers: Christophe Come, Director - Pharmacology, Adcendo ApS, Andreas Norlin, Chief Scientific Officer, Ascelia Pharma, Nina Reschke, Head of Biology, Senior Director, Bright Peak Therapeutics, Lene Lene, Research Scientist, CataVax, Ludovic Bigot, Project manager, Gustave Roussy, Adam Robertson, Chief Scientific Officer, Hemispherian, Peter Holst, Owner and Chief Executive and Science Officer, Hervolution Therapeutics, Paulina Zydowicz-Machtel, Preclinical Specialist, JJP Biologics, Srustidhar Das, Senior Research Scientist, Karolinska Institutet, Anil Thotakura, Head of Immuno-Oncology, King Fisher Marine Service LP, Rocio Evangelista, Head of Animal Facility, Molecular Partners AG, Maria Kiratzis, Research Associate, Roche, Manel Merabet, Chief Development Officer, SKYMAB Biotherapeutics, Ilona Prochazkova, Preclinical Development Scientist, SOTIO Biotech a.s.